JP2013518128A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013518128A5 JP2013518128A5 JP2012551318A JP2012551318A JP2013518128A5 JP 2013518128 A5 JP2013518128 A5 JP 2013518128A5 JP 2012551318 A JP2012551318 A JP 2012551318A JP 2012551318 A JP2012551318 A JP 2012551318A JP 2013518128 A5 JP2013518128 A5 JP 2013518128A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- rap
- agent
- item
- peptide complex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 34
- 239000000863 peptide conjugate Substances 0.000 claims description 13
- 102000012086 alpha-L-Fucosidase Human genes 0.000 claims description 12
- 108010061314 alpha-L-Fucosidase Proteins 0.000 claims description 12
- 239000003112 inhibitor Substances 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 108010071471 glutamyl-leucyl-lysyl-valyl-leucyl-methionyl-glutamyl-lysyl-glutamyl-leucine Proteins 0.000 claims description 10
- 206010019695 Hepatic neoplasm Diseases 0.000 claims description 9
- 208000014018 liver neoplasm Diseases 0.000 claims description 9
- 229940127089 cytotoxic agent Drugs 0.000 claims description 7
- 150000001413 amino acids Chemical class 0.000 claims description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 4
- 239000004472 Lysine Substances 0.000 claims description 4
- 239000002254 cytotoxic agent Substances 0.000 claims description 4
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 4
- 239000000412 dendrimer Substances 0.000 claims description 4
- 229920000736 dendritic polymer Polymers 0.000 claims description 4
- 208000006454 hepatitis Diseases 0.000 claims description 4
- 231100000283 hepatitis Toxicity 0.000 claims description 4
- 229920001184 polypeptide Polymers 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 230000009385 viral infection Effects 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- 239000003443 antiviral agent Substances 0.000 claims description 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 3
- QPXXQIKORIGFSB-UTINFBMNSA-N (3r,4r,5s,6s)-1-butyl-4,5,6-trihydroxyazepane-3-carboxylic acid Chemical compound CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H](C(O)=O)C1 QPXXQIKORIGFSB-UTINFBMNSA-N 0.000 claims description 2
- 206010016654 Fibrosis Diseases 0.000 claims description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 2
- 208000033981 Hereditary haemochromatosis Diseases 0.000 claims description 2
- 206010067125 Liver injury Diseases 0.000 claims description 2
- 102000013529 alpha-Fetoproteins Human genes 0.000 claims description 2
- 108010026331 alpha-Fetoproteins Proteins 0.000 claims description 2
- AFRPVDHJWCJLNM-UHFFFAOYSA-N beta-1-C-ethyl-deoxymannojirimycin Natural products CCC1NC(CO)C(O)C(O)C1O AFRPVDHJWCJLNM-UHFFFAOYSA-N 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 230000007882 cirrhosis Effects 0.000 claims description 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 2
- 229960004679 doxorubicin Drugs 0.000 claims description 2
- 229960002949 fluorouracil Drugs 0.000 claims description 2
- 231100000753 hepatic injury Toxicity 0.000 claims description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 2
- 231100000331 toxic Toxicity 0.000 claims description 2
- 230000002588 toxic effect Effects 0.000 claims description 2
- 230000002285 radioactive effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 16
- 239000000562 conjugate Substances 0.000 description 2
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000002767 hepatic artery Anatomy 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- -1 radioisotopes Substances 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29917710P | 2010-01-28 | 2010-01-28 | |
| US61/299,177 | 2010-01-28 | ||
| PCT/US2011/022917 WO2011094536A1 (en) | 2010-01-28 | 2011-01-28 | Method for treating liver disorders with receptor associated protein ( irp) peptide-fucosidase inhibitor conjugates |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016043181A Division JP2016145231A (ja) | 2010-01-28 | 2016-03-07 | 受容体関連タンパク質（ｒａｐ）ペプチド−フコシダーゼ阻害薬複合体による肝障害処置のための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013518128A JP2013518128A (ja) | 2013-05-20 |
| JP2013518128A5 true JP2013518128A5 (enExample) | 2014-02-20 |
| JP6170675B2 JP6170675B2 (ja) | 2017-07-26 |
Family
ID=44319804
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012551318A Expired - Fee Related JP6170675B2 (ja) | 2010-01-28 | 2011-01-28 | 受容体関連タンパク質（ｒａｐ）ペプチド−フコシダーゼ阻害薬複合体による肝障害処置のための方法 |
| JP2016043181A Pending JP2016145231A (ja) | 2010-01-28 | 2016-03-07 | 受容体関連タンパク質（ｒａｐ）ペプチド−フコシダーゼ阻害薬複合体による肝障害処置のための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016043181A Pending JP2016145231A (ja) | 2010-01-28 | 2016-03-07 | 受容体関連タンパク質（ｒａｐ）ペプチド−フコシダーゼ阻害薬複合体による肝障害処置のための方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20110189084A1 (enExample) |
| EP (1) | EP2528613B1 (enExample) |
| JP (2) | JP6170675B2 (enExample) |
| KR (1) | KR101784539B1 (enExample) |
| CN (1) | CN102905716B (enExample) |
| AU (1) | AU2011210756B2 (enExample) |
| CA (1) | CA2788175A1 (enExample) |
| ES (1) | ES2555555T3 (enExample) |
| TW (1) | TWI558397B (enExample) |
| WO (1) | WO2011094536A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8956859B1 (en) | 2010-08-13 | 2015-02-17 | Aviex Technologies Llc | Compositions and methods for determining successful immunization by one or more vaccines |
| RU2474423C1 (ru) * | 2011-12-20 | 2013-02-10 | Федеральное государственное бюджетное учреждение науки Институт общей физики им. А.М. Прохорова Российской академии наук (ИОФ РАН) | Способ лечения метастазов печени |
| US10442868B2 (en) * | 2013-03-14 | 2019-10-15 | Rhode Island Hospital, A Lifespan-Partner | Treating hepatitis B virus infections by administering receptor associated protein (RAP) |
| BR112018000961A2 (pt) * | 2015-07-30 | 2018-09-18 | Horizon Orphan Llc | inibidores de fucosidase |
| CN114174263B (zh) * | 2019-05-10 | 2025-01-10 | 阿勒克图治疗公司 | 非溶酶体葡糖神经酰胺酶抑制剂及其用途 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4394448A (en) * | 1978-02-24 | 1983-07-19 | Szoka Jr Francis C | Method of inserting DNA into living cells |
| US4391904A (en) | 1979-12-26 | 1983-07-05 | Syva Company | Test strip kits in immunoassays and compositions therein |
| US5186941A (en) * | 1983-05-06 | 1993-02-16 | Vestar, Inc. | Vesicle formulation for the controlled release of therapeutic agents |
| US5096909A (en) * | 1989-06-27 | 1992-03-17 | Monsanto Company | Fucosidase inhibitor |
| US5017704A (en) * | 1989-06-27 | 1991-05-21 | Monsanto Company | Fucosidase inhibitor |
| US5100797A (en) * | 1989-06-27 | 1992-03-31 | Monsanto Company | Fucosidase inhibitors |
| US5153325A (en) * | 1989-06-27 | 1992-10-06 | Monsanto Company | Fucosidase inhibitor |
| US5240707A (en) * | 1990-04-12 | 1993-08-31 | Merrell Dow Pharma | Alpha-mannosidase and fucosidase inhibitors |
| ZA912588B (en) * | 1990-04-12 | 1992-01-29 | Merrell Dow Pharma | Novel alpha-mannosidase and fucosidase inhibitors |
| US5474766A (en) | 1992-12-18 | 1995-12-12 | Washington University | Methods and compositions for inhibition of hepatic clearance of tissue-type plasminogen activator |
| TW492882B (en) * | 1997-11-28 | 2002-07-01 | Caleb Pharmaceuticals Inc | Cholinergic antagonist plaster composition |
| US6589954B1 (en) * | 1998-05-22 | 2003-07-08 | Scios, Inc. | Compounds and methods to treat cardiac failure and other disorders |
| US6274597B1 (en) * | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| US7816560B1 (en) * | 1999-08-10 | 2010-10-19 | Thomas Jefferson University | Long chain n-alkyl compounds and oxa-derivatives thereof |
| US6261595B1 (en) | 2000-02-29 | 2001-07-17 | Zars, Inc. | Transdermal drug patch with attached pocket for controlled heating device |
| ATE429233T1 (de) * | 2001-06-29 | 2009-05-15 | Glykos Finland Oy | Verwendung mindestens einer glycoinhibitor- substanz gegen infektionskrankheiten |
| US6852842B2 (en) | 2002-08-26 | 2005-02-08 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Methods for functional kidney imaging using small dendrimer contrast agents |
| US20050026823A1 (en) * | 2003-06-20 | 2005-02-03 | Biomarin Pharmaceutical Inc. | Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues |
| CA2525236C (en) * | 2003-06-20 | 2015-03-24 | Biomarin Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
| US20060198819A1 (en) | 2003-08-08 | 2006-09-07 | Novo Nordisk Healthcare A/G | Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest |
| WO2007012001A1 (en) | 2005-07-18 | 2007-01-25 | The Scripps Research Institute | Method for making amphiphilic dendrimers |
| US8188563B2 (en) | 2006-07-21 | 2012-05-29 | The Regents Of The University Of California | Shallow-trench-isolation (STI)-bounded single-photon CMOS photodetector |
| CN101594878A (zh) * | 2006-09-18 | 2009-12-02 | 雷普特药品公司 | 通过给予受体相关蛋白（rap）-缀合物对肝病症的治疗 |
| US20080116171A1 (en) * | 2006-11-22 | 2008-05-22 | Clarkson University | Method For The Preferential Polishing Of Silicon Nitride Versus Silicon Oxide |
| KR20100015786A (ko) * | 2007-03-21 | 2010-02-12 | 랩터 파마슈티컬 인코포레이티드 | 환형의 수용체-연관된 단백질(ｒａｐ) 펩티드 |
| US8236753B2 (en) * | 2007-12-10 | 2012-08-07 | The Brigham And Women's Hospital, Inc. | RAP variants for drug delivery and methods of use thereof |
| US8252834B2 (en) | 2008-03-12 | 2012-08-28 | The Regents Of The University Of Michigan | Dendrimer conjugates |
-
2011
- 2011-01-28 WO PCT/US2011/022917 patent/WO2011094536A1/en not_active Ceased
- 2011-01-28 CA CA2788175A patent/CA2788175A1/en not_active Abandoned
- 2011-01-28 ES ES11737725.9T patent/ES2555555T3/es active Active
- 2011-01-28 TW TW100103531A patent/TWI558397B/zh not_active IP Right Cessation
- 2011-01-28 AU AU2011210756A patent/AU2011210756B2/en not_active Ceased
- 2011-01-28 EP EP11737725.9A patent/EP2528613B1/en not_active Not-in-force
- 2011-01-28 KR KR1020127022072A patent/KR101784539B1/ko not_active Expired - Fee Related
- 2011-01-28 CN CN201180016788.XA patent/CN102905716B/zh not_active Expired - Fee Related
- 2011-01-28 US US13/016,135 patent/US20110189084A1/en not_active Abandoned
- 2011-01-28 JP JP2012551318A patent/JP6170675B2/ja not_active Expired - Fee Related
-
2016
- 2016-03-07 JP JP2016043181A patent/JP2016145231A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1340603C (en) | Tri-aza macrocycles and metal complexes thereof | |
| JP2013518128A5 (enExample) | ||
| Moreno et al. | Reduction of advanced liver fibrosis by short‐term targeted delivery of an angiotensin receptor blocker to hepatic stellate cells in rats | |
| JP2008195715A5 (enExample) | ||
| JP2018506550A5 (enExample) | ||
| TWI549690B (zh) | 包含抗－ｃｄ１９類美登素（ｍａｙｔａｎｓｉｎｏｉｄ）免疫結合物及利妥昔單抗（ｒｉｔｕｘｉｍａｂ）之用於治療ｃｄ１９＋ｂ－細胞惡性症狀之組合療法 | |
| JP3054346B2 (ja) | ペプチド類 | |
| JP2012102122A5 (enExample) | ||
| TW201026335A (en) | Selective seprase inhibitors | |
| JP2020520382A5 (enExample) | ||
| JP2011132258A (ja) | 改良放射性金属錯体組成物 | |
| JP2013518086A5 (enExample) | ||
| EP3906061A1 (en) | Methods for treating cancer using combinations of parp inhibitors and antibody radioconjugates | |
| JP2008515889A5 (enExample) | ||
| CA2949365A1 (en) | One-step labeling of antibodies to high specific activity with actinium-225 | |
| TW201740979A (zh) | 熱休克蛋白（ｈｓｐ）９０抑制劑藥物共軛物 | |
| US20030023050A1 (en) | Actinium-225 complexes and conjugates for targeted radiotherapy | |
| CN110612109A (zh) | 使用BCL-2抑制剂连同α-发射放射免疫治疗来治疗癌症的方法 | |
| Colleoni et al. | A phase II study of mitoxantrone combined with beta‐interferon in unresectable hepatocellular carcinoma | |
| JP2004524323A5 (enExample) | ||
| KR20080099279A (ko) | 이관능성 레조르시놀, 티오레조르시놀, 및 디티오레조르시놀 유도체 금속 킬레이팅 컨쥬게이트 | |
| AU2020257135B2 (en) | Radiotherapeutic and companion imaging agents to target MC1R | |
| WO2020238800A1 (zh) | 用于肿瘤的靶向放射性药物及其在影像指导下的靶向放射治疗与免疫治疗的联合疗法 | |
| Imam | Status of radioimmunotherapy in the new millennium | |
| KR20080072686A (ko) | 이관능성 금속 킬레이팅 컨쥬게이트 |